Department of Medical Oncology, Cochin Hospital, AP-HP, CARPEM, France; Immunomodulatory Therapies Multidisciplinary Study Group (CERTIM), Paris, France.
Department of Medical Oncology, Cochin Hospital, AP-HP, CARPEM, France; Immunomodulatory Therapies Multidisciplinary Study Group (CERTIM), Paris, France.
Clin Nutr ESPEN. 2024 Dec;64:44-50. doi: 10.1016/j.clnesp.2024.09.002. Epub 2024 Sep 6.
BACKGROUND & AIMS: We previously reported in the ELY prospective study that increased resting energy expenditure (REE) - so-called hypermetabolism - worsened tumor response, 6-month progression-free (PFS) and overall survival (OS) in metastatic non-small cell lung cancer (mNSCLC) patients treated with immune checkpoint inhibitors (ICI). Here, we investigated the effect of caloric coverage on the sensitivity to ICI.
We retrospectively analysed a multicentric database of mNSCLC patients treated with ICI. All patients had a baseline nutritional assessment including REE measured with indirect calorimetry and a dietitian estimation of food intakes. Measured/theoretical REE ≥110% defined hypermetabolism. Intakes ≥90% of estimated needs defined caloric coverage. The primary endpoint was PFS. Secondary endpoints included response rate and OS.
Among 162 patients, 84 (51.9%) were normometabolic, and 78 (48.1%) hypermetabolic. In hypermetabolic patients, 40 (51.3%) met their caloric needs (group A) while 38 (48.7%) did not (group B). Median PFS was 4.3 vs. 1.9 months in groups A and B, respectively (HR: 0.49, 95%CI [0.31-0.80], p = 0.004). The PFS achieved in the group A and in normometabolic patients were similar (HR: 0.99, 95%CI [0.65-1.51], p = 0.95). In multivariate analysis, caloric coverage was independently associated with improved PFS in hypermetabolic patients (HR: 0.56, 95%CI [0.31-0.99], p = 0.048). Among hypermetabolic patients, the median OS was higher in the group A (HR: 0.58, 95%CI [0.35-0.95], p = 0.03).
Energy supply is a critical determinant of the sensitivity to ICI in NSCLC patients. A randomized study to evaluate the benefit of early nutritional intervention is warranted.
我们之前在 ELY 前瞻性研究中报告称,在接受免疫检查点抑制剂(ICI)治疗的转移性非小细胞肺癌(mNSCLC)患者中,静息能量消耗(REE)增加(所谓的高代谢)会导致肿瘤反应、6 个月无进展(PFS)和总生存(OS)恶化。在此,我们研究了热量覆盖对 ICI 敏感性的影响。
我们回顾性分析了接受 ICI 治疗的 mNSCLC 患者的多中心数据库。所有患者均接受基线营养评估,包括间接测热法测量 REE 和营养师估计的食物摄入量。测量/理论 REE≥110%定义为高代谢。摄入量≥估计需求的 90%定义为热量覆盖。主要终点是 PFS。次要终点包括反应率和 OS。
在 162 名患者中,84 名(51.9%)为正常代谢,78 名(48.1%)为高代谢。在高代谢患者中,40 名(51.3%)满足其热量需求(A 组),而 38 名(48.7%)未满足(B 组)。A 组和 B 组的中位 PFS 分别为 4.3 个月和 1.9 个月(HR:0.49,95%CI [0.31-0.80],p=0.004)。A 组和正常代谢患者的 PFS 相似(HR:0.99,95%CI [0.65-1.51],p=0.95)。多变量分析显示,热量覆盖与高代谢患者的 PFS 改善独立相关(HR:0.56,95%CI [0.31-0.99],p=0.048)。在高代谢患者中,A 组的中位 OS 更高(HR:0.58,95%CI [0.35-0.95],p=0.03)。
能量供应是 NSCLC 患者对 ICI 敏感性的关键决定因素。需要进行一项随机研究来评估早期营养干预的益处。